Cost-effectiveness analysis of dyevert™ Power XT in patients with chronic kidney disease undergoing percutaneous coronary intervention procedures in Spain.
Jose Ramon Lopez-MinguezA L Martín de FranciscoM J SolerFelipe Hernandez HernandezRaul MorenoEduardo PinarA SampedroMareque MaríaI OyagüezPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2023)
The use of Dyevert™ Power XT resulted dominant option, due to its higher effectiveness and lower cost as compared to standard clinical practice and, therefore, a preferred option in patients with CKD stages 3b-4 undergoing PCI in Spain.
Keyphrases
- percutaneous coronary intervention
- clinical practice
- st segment elevation myocardial infarction
- acute myocardial infarction
- acute coronary syndrome
- st elevation myocardial infarction
- coronary artery disease
- antiplatelet therapy
- coronary artery bypass grafting
- randomized controlled trial
- atrial fibrillation
- systematic review
- chronic kidney disease
- coronary artery bypass
- heart failure
- left ventricular